Pharmaxis is a specialty pharmaceutical company involved in the research, development and commercialisation of new therapies for undertreated respiratory diseases.
The company’s first product, Aridol, is approved for sale in Australia, major European countries and Korea. It is designed to identify the tightening of airways that is a hallmark of asthma, and assist in diagnosing and managing the disease.
Our second product, Bronchitol, is in final clinical trials as a new treatment for the debilitating lung diseases bronchiectasis and cystic fibrosis.
We are committed to bringing our therapeutic advances for respiratory and immune diseases to patients throughout the world, and to building an internationally successful pharmaceutical business: one that’s built to last.
Company overview
